A Study of Talquetamab With Other Anticancer Therapies in Participants With Multiple Myeloma

To join this study, you must have been diagnosed with multiple myeloma and your doctors need to be able to measure your cancer – for example, through blood or urine tests. You should also generally be well enough to take part in a study, meaning you can perform most of your usual daily activities without too much difficulty.

There are some reasons why you might not be able to join. For example, if you've recently had certain vaccines or have received a high dose of steroid medicines in the past two weeks. Also, if your multiple myeloma is affecting your brain or spinal cord, or if you have certain other serious medical conditions like a history of stroke or seizures within the last six months, you wouldn't be able to participate. Women must also meet specific pregnancy prevention requirements.

If you decide to take part in this study, you will receive talquetamab along with one of the other mentioned anticancer therapies. You'll have regular appointments at the hospital or clinic where the research team will monitor your health very closely. These appointments will involve physical exams, blood tests, and other checks to see how you are responding to the treatment and to keep an eye on any side effects.

The specific number of visits and tests will vary depending on which treatment combination you receive and how long you are on the study. The study team will explain everything in detail, including how long you are expected to receive treatment and any follow-up appointments after that. The total duration of participation will depend on how you respond to the treatment and the study plan, but detailed information will be provided before you agree to participate.